Neuronetics (STIM) and Greenbrook (GBNH), a leading provider of transcranial magnetic stimulation therapy announced an expanded commercial partnership through year end 2028. Under the partnership agreement, Neuronetics will be the exclusive supplier of TMS equipment to Greenbrook. Over time, Neuronetics’ NeuroStar devices will replace competitive TMS devices at Greenbrook locations. The Companies will work jointly to grow through co-branding and co-marketing programs, enhanced patient and clinician awareness, improved patient access to care, and collaboration on product development and publications. The agreement also has minimum purchase commitments, and all treatment session purchases will convert to a "per-click" consumable model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STIM:
- Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Neuronetics: Data confirms NeuroStar effective treatment for anxious depression
- Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
- Neuronetics settles litigation against Brainsway